Faeth Therapeutics, Inc. Operating Cash Flow
Faeth Therapeutics, Inc. (FTH) reported Operating Cash Flow of -$26.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.67M.
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$10.73M.
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.86M.
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.59M.
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$20.45M.
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$24.67M.
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$32.02M.
- Faeth Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$39.03M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$26.41M 10-Q · filed 2026-08-04 | -$30.27M derived: sum of 3 quarters · filed 2026-08-04 | -$33.86M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$10.73M 10-Q · filed 2026-05-15 | -$14.60M derived: sum of 2 quarters · filed 2026-05-15 | -$18.18M derived: sum of 3 quarters · filed 2026-05-15 | -$24.09M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$7.45M derived: sum of 2 quarters · filed 2026-03-30 | -$13.36M derived: sum of 3 quarters · filed 2026-08-04 | -$20.45M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$3.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$9.49M derived: sum of 2 quarters · filed 2026-08-04 | -$16.59M 10-Q · filed 2025-11-14 | -$22.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$5.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$13.00M 10-Q · filed 2026-08-04 | -$18.80M derived: sum of 3 quarters · filed 2026-08-04 | -$24.27M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$7.09M 10-Q · filed 2026-05-15 | -$12.89M derived: sum of 2 quarters · filed 2026-05-15 | -$18.36M derived: sum of 3 quarters · filed 2026-05-15 | -$24.15M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$11.26M derived: sum of 2 quarters · filed 2026-03-30 | -$17.05M derived: sum of 3 quarters · filed 2026-03-30 | -$24.67M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$5.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$11.26M derived: sum of 2 quarters · filed 2025-11-14 | -$18.88M 10-Q · filed 2025-11-14 | -$25.04M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$5.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$13.41M 10-Q · filed 2025-08-05 | -$19.57M derived: sum of 3 quarters · filed 2025-08-05 | -$24.23M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$7.62M 10-Q · filed 2025-05-06 | -$13.78M derived: sum of 2 quarters · filed 2025-05-06 | -$18.44M derived: sum of 3 quarters · filed 2025-05-06 | -$27.90M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$10.82M derived: sum of 2 quarters · filed 2025-03-28 | -$20.29M derived: sum of 3 quarters · filed 2025-03-28 | -$32.02M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$4.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$14.12M derived: sum of 2 quarters · filed 2024-11-14 | -$25.86M 10-Q · filed 2024-11-14 | -$35.43M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$9.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$21.20M 10-Q · filed 2024-08-06 | -$30.77M derived: sum of 3 quarters · filed 2024-08-06 | -$37.58M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$11.74M 10-Q · filed 2024-05-09 | -$21.31M derived: sum of 2 quarters · filed 2024-05-09 | -$28.11M derived: sum of 3 quarters · filed 2024-05-09 | -$40.01M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$9.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$16.38M derived: sum of 2 quarters · filed 2024-02-29 | -$28.28M derived: sum of 3 quarters · filed 2024-02-29 | -$39.03M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$18.70M derived: sum of 2 quarters · filed 2023-11-07 | -$29.45M 10-Q · filed 2023-11-07 | -$37.32M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$11.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$22.65M 10-Q · filed 2023-08-03 | -$30.52M derived: sum of 3 quarters · filed 2023-08-03 | -$36.09M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$10.75M 10-Q · filed 2023-05-09 | -$18.62M derived: sum of 2 quarters · filed 2023-05-09 | -$24.20M derived: sum of 3 quarters · filed 2023-05-09 | -$30.24M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$13.45M derived: sum of 2 quarters · filed 2023-03-29 | -$19.49M derived: sum of 3 quarters · filed 2023-03-29 | -$30.26M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$11.62M derived: sum of 2 quarters · filed 2022-11-08 | -$22.39M 10-Q · filed 2022-11-08 | -$25.07M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$16.81M 10-Q · filed 2022-08-09 | -$19.49M derived: sum of 3 quarters · filed 2022-08-09 | -$25.29M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$10.77M 10-Q · filed 2022-05-10 | -$13.45M derived: sum of 2 quarters · filed 2022-05-10 | -$19.25M derived: sum of 3 quarters · filed 2022-05-10 | -$22.01M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$8.48M derived: sum of 2 quarters · filed 2022-03-15 | -$11.24M derived: sum of 3 quarters · filed 2022-03-15 | -$17.70M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$5.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$8.56M derived: sum of 2 quarters · filed 2021-11-10 | -$15.03M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$9.23M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$6.46M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |